CV Sciences Inc (CVSI)

[Wolf-man jack]

WQLF SAYS : Only The Shadow Knows YQU Will Understand YQU Understand. HAVE MERCY WQLF ahoooooo

Dr Joong J Fang Said: Those that lack common sense , need to take a course in Simple Logic.
Why did CV SCIENCES attempt to acquire extract labs How many shares were needed for the acquisition, and where will these shares come from? That's Right, from the 34 million Shares set aside for Acquisitions, employees, consultants, and and not working capital. The Shares given to Extract Labs would have been estimated around 25 Million at $0.04 cents per share.At $.03 cents per share would come to 33,333,333 Shares. That 34 Million shares in the Evergreen Plan and of needed the 4 percent increase for 10 years would be sufficient for the Employees and the Acquisition of Extract Labs. Extract Labs would then be able to receive 1 Million Dollars worth of CVSI Restricted stock.

Ai Generated:

CV Sciences attempted to acquire Extract Labs to accelerate growth, expand its customer base, and strengthen its position in the cannabinoid market. The strategic acquisition aimed to leverage Extract Labs’ manufacturing capabilities for in-sourcing production, reducing costs, and boosting CV Sciences’ +PlusCBD™ brand, despite later disputes over the deal's termination.

Key reasons for the acquisition attempt included:

Enhanced Manufacturing & Supply Chain: Extract Labs' GMP-certified and FDA-registered facilities allowed for increased, high-quality production, including gummies, topicals, and tinctures.

Cost Savings & Efficiency: The move was designed to in-source production of CV Sciences’ products, improving operational efficiency and lowering costs.

Market Expansion & Product Line Growth: The acquisition intended to expand CV Sciences’, B2B and B2C reach by incorporating Extract Labs' specialized, high-quality product portfolio.

Financial Growth: CV Sciences sought to address recent revenue declines and enhance shareholder value by acquiring a profitable stand-alone business.

Although a definitive agreement was announced in November 2024, the acquisition faced complications in early 2025 due to a purported termination by the sellers, which CV Sciences is currently contesting.

Ai Generated:

In the proposed acquisition of Extract Labs by CV Sciences announced in November 2024, the consideration included an initial issuance of CV Sciences common stock valued at $1 million.

Key details regarding the share offer include:

Initial Shares: The number of shares was based on the 60-day volume-weighted average price (VWAP) of CV Sciences' common stock.

Additional Shares (Earnout): The sellers were eligible to receive up to $600,000 in additional shares of CV Sciences common stock, dependent on Extract Labs achieving specific revenue targets over the two 12-month periods following the closing.

Cash Component: In addition to the shares, a cash payment of $400,000 was part of the initial consideration.

Status: While announced in Nov 2024 with an expected closing in Q1 2025, the acquisition has been disputed due to a purported termination by the sellers.

Note: The specific number of shares is not explicitly stated in the announcement, as it was pegged to the market price (VWAP) at the time of closing.

Wolf Said: The Second Time Around or Another Target You Understand. HAVE MERCY ahoooooo
Here is the extended version for the extension you understand ahooo

https://share.google/Q9lQDbCteHcdZGCPW